Jihong Wang1, Travis Salzillo2, Yongying Jiang3, Yuri Mackeyev4, Clifton David Fuller2, Caroline Chung2, Seungtaek Choi2, Neil Hughes2, Yao Ding5, Jinzhong Yang5, Sastry Vedam6, Sunil Krishnan4. 1. Department of Radiation Physics, MD Anderson Cancer Center, Houston, United States. Electronic address: Jihong.Wang@mdanderson.org. 2. Department of Radiation Oncology, MD Anderson Cancer Center, Houston, United States. 3. The Institute for Applied Cancer Science, MD Anderson Cancer Center, Houston, United States. 4. Department of Radiation Oncology, Mayo Clinic, Jacksonville, United States. 5. Department of Radiation Physics, MD Anderson Cancer Center, Houston, United States. 6. Department of Radiation Oncology, University of Maryland, Baltimore, United States.
Abstract
BACKGROUND: Gadolinium-based contrast is often used when acquiring MR images for radiation therapy planning for better target delineation. In some situations, patients may still have residual MRI contrast agents in their tissue while being treated with high-energy radiation. This is especially true when MRI contrast agents are administered during adaptive treatment replanning for patients treated on MR-Linac systems. PURPOSE: The purpose of this study was to analyze the molecular stability of MRI contrast agents when exposed to high energy photons and the associated secondary electrons in a 1.5T MR-Linac system. This was the first step in assessing the safety of administering MRI contrast agents throughout the course of treatment. MATERIALS AND METHODS: Two common MRI contrast agents were irradiated with 7 MV photons to clinical dose levels. The irradiated samples were analyzed using liquid chromatography-high resolution mass spectrometry to detect degradation products or conformational alterations created by irradiation with high energy photons and associated secondary electrons. RESULTS: No significant change in chemical composition or displacement of gadolinium ions from their chelates was discovered in samples irradiated with 7 MV photons at relevant clinical doses in a 1.5T MR-Linac. Additionally, no significant correlation between concentrations of irradiated MRI contrast agents and radiation dose was observed. CONCLUSION: The chemical composition stability of the irradiated contrast agents is promising for future use throughout the course of patient treatment. However, in vivo studies are needed to confirm that unexpected metabolites are not created in biological milieus. Published by Elsevier B.V.
BACKGROUND: Gadolinium-based contrast is often used when acquiring MR images for radiation therapy planning for better target delineation. In some situations, patients may still have residual MRI contrast agents in their tissue while being treated with high-energy radiation. This is especially true when MRI contrast agents are administered during adaptive treatment replanning for patients treated on MR-Linac systems. PURPOSE: The purpose of this study was to analyze the molecular stability of MRI contrast agents when exposed to high energy photons and the associated secondary electrons in a 1.5T MR-Linac system. This was the first step in assessing the safety of administering MRI contrast agents throughout the course of treatment. MATERIALS AND METHODS: Two common MRI contrast agents were irradiated with 7 MV photons to clinical dose levels. The irradiated samples were analyzed using liquid chromatography-high resolution mass spectrometry to detect degradation products or conformational alterations created by irradiation with high energy photons and associated secondary electrons. RESULTS: No significant change in chemical composition or displacement of gadolinium ions from their chelates was discovered in samples irradiated with 7 MV photons at relevant clinical doses in a 1.5T MR-Linac. Additionally, no significant correlation between concentrations of irradiated MRI contrast agents and radiation dose was observed. CONCLUSION: The chemical composition stability of the irradiated contrast agents is promising for future use throughout the course of patient treatment. However, in vivo studies are needed to confirm that unexpected metabolites are not created in biological milieus. Published by Elsevier B.V.
Entities:
Keywords:
Contrast media; Gadolinium; Magnetic resonance imaging; Mass spectrometry; Radiotherapy
Authors: Ashkan A Malayeri; Kristina M Brooks; L Henry Bryant; Robert Evers; Parag Kumar; Daniel S Reich; David A Bluemke Journal: J Am Coll Radiol Date: 2016-01-23 Impact factor: 5.532
Authors: Ernst S Kooreman; Vivian van Pelt; Marlies E Nowee; Floris Pos; Uulke A van der Heide; Petra J van Houdt Journal: Front Oncol Date: 2022-06-07 Impact factor: 5.738
Authors: Samuel L Mulder; Jolien Heukelom; Brigid A McDonald; Lisanne Van Dijk; Kareem A Wahid; Keith Sanders; Travis C Salzillo; Mehdi Hemmati; Andrew Schaefer; Clifton D Fuller Journal: Cancers (Basel) Date: 2022-04-10 Impact factor: 6.575